samedan logo
 
 
 
spacer
home > ebr > autumn 2001 > dendritic cells for cancer immunotherapy
PUBLICATIONS
European Biopharmaceutical Review

Dendritic Cells for Cancer Immunotherapy

Cancer is one of the major killers in the developed world, accounting for over one million deaths in North America and Europe annually. In the US, the annual incidence of cancer is approximately 1,200,000, and the number of people dying of the disease each year is about 500,000 (1). The American Cancer Society estimates that one in three Americans will develop cancer in his or her lifetime. Between 1970 and 1990, the overall five-year survival rate of treated cancer patients improved by about 10 per cent as a result of earlier detection, improved radio- and chemotherapies and, possibly, changes in living habits. However, with the exception of small cell lung carcinoma and breast cancer, improvement in advanced stages has been negligible. Moreover, the lack of specificity of radio- and chemotherapies causes severe side effects. Therefore, new therapies with better efficacy and specificity are needed.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Jean-Pierre Abastado, Vice-President, Scientific Affairs, IDM

Jean-Pierre Abastado is Vice-President in charge of Scientific Affairs at IDM. He is on leave from the CNRS, where he is Research Director. He graduated from the Ecole Polytechnique in 1978 and obtained his PhD in biological sciences from the University of Paris VI in 1986. From 1979 to 1998, he held several positions at the Pasteur Institute (in Paris, France) and NIH (in Bethesda, US). From 1990 to 1998, he managed a group of eight people in the unit of Professor Philippe Kourilsky, specialising in molecular biology and fundamental immunology. Between 1994 and 1998 he was named, on several occasions, an independent expert by the Pasteur Institute, Pasteur-Mérieux Sérums et Vaccins and INSERM. He is the Author of more than 80 scientific publications and of several patent applications in France and the US.

spacer
Jean-Pierre Abastado
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

IBM Research and Arctoris Accelerate Closed Loop Drug Discovery with AI and Cloud

Oxford and Zurich – 13 September 2021 – Life Science Newswire – Today, IBM Research and Arctoris announced they are investigating the application of AI and automation to accelerate closed loop molecule discovery. IBM Research has developed RXN for Chemistry, an online platform leveraging state-of-the-art Natural Language Processing (NLP) architectures to automate synthetic chemistry.
More info >>

White Papers

The Role of the CRO in Effective Risk-Based Monitoring

Medpace

The clinical trial industry is evolving. In an effort to improve participant safety and data integrity, regulators are encouraging trial sponsors to transition from a focused on-site monitoring approach they have traditionally employed toward a risk-based approach that utilizes a combination of centralized and on-site monitoring techniques to ensure patient safety and data quality. The Risk-Based Monitoring (RBM) paradigm has many potential advantages over established monitoring practices including enhanced patient safety and data integrity, more efficient and effective protocol design, reduced costs, and the ability to strategically adjust oversight in keeping with changes in risk level.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement